Keywords
SARS-CoV-2
Haemoglobin Genotype
Lagos
Nigeria
How to Cite
Abstract
COVID‐19 pandemic has posed unique challenges to the health providers involved with chronic diseases like Haemoglobin disorders (sickle cell disease). Therefore, this study highlights the susceptibility and severity of COVID‐19 associated with normal and haemoglobin variants.
This study is a case series that includes patients evaluated between June and August 30, 2020, and diagnosed with COVID-19 by the Quantitative Polymerase Chain Reaction method. Alkaline haemoglobin electrophoresis was used to identify types of Haemoglobin genotype associated with mild-to-severe cases of COVID-19. A total of 697 COVID-19 patients were included in this study, with a mean age of 41.32 (12.917). There were more males (66.1%) than females. The most frequently detected genotype was AA (75.8%), followed by AS (22%). Severe conditions of COVID-19 were present in patients with HBAC 2(14.28%) and HBAS 13 (8.5%). Co-morbidities were present in (24.0%) of the patients, with a mortality rate of 1.3%. Patients with pneumonia in association with other co-morbidities are 26 times more likely to have severe SARS CoV-2 than those with only pneumonia, irrespective of their haemoglobin genotype profile. The clinical course is seen in normal haemoglobin, and the variant with COVID-19 was the same. It is suggested that people with haemoglobin variant are not at increased risk during COVID-19 infection or risk of a sickle cell crisis.
References
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.105924
Puca E, Čivljak R, Arapović J, Popescu C, Christova I, Raka L, et al. Short epidemiological overview of the current situation on COVID-19 pandemic in Southeast European (SEE) countries. J Infect Dev Ctries. 2020; 14(5):433-437. https://doi.org/10.3855/jidc.12814
Wenzhong L, Hualan L. COVID-19: attacks the 1-beta Chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. https://doi.org/1026434/chemrxiv.11938173:v6
Wenzhong L, Hualan L. COVID-19: attacks the 1-beta Chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. https://doi.org/1026434/chemrxiv.11938173:v6
Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021; 11(1): 4263. https://doi.org/10.1038/s41598-021-82862-5
Liu, W and Li, H. COVID-19 disease: ORF8 and surface glycoprotein inhibit heme metabolism by binding to porphyrin. ChemRxiv 10.26434/chemrxiv
Naik RP, Smith-Whitley K, Hassell KL, Umeh NI, de Montalembert M, Sahota P, et al. Clinical outcomes associated with sickle cell trait: a systematic review. Ann Intern Med. 2018; 169(9):619‐627. https://doi.org/10.7326/m18-1161
Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009;200(6): 620.e1‐620.e3. https://doi.org/10.1016/j.ajog.2009.01.038
Kehinde TA, Osundiji MA. Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review Eur J Haematol. 2020;105(5):519-523. https://doi.org/10.1111/ejh.13478
Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID‐19 infection in patients with sickle cell disease. Br J Haematol. 2020;189(5):851‐852. https://doi.org/10.1111/bjh.16734
McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID‐19 infection and sickle cell disease: a UK centre experience. Br J Haematol. 2020;190(2):e57-e58. https://doi.org/10.1111/bjh.16779
De Luna G, Habibi A, Deux JF, Colard M, Pham Hung d'Alexandry d'Orengiani AL, Schlemmer F, et al. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020 ;95 (7):876‐878. https://doi.org/10.1002/ajh.25833
Naik RP, Smith-Whitley K, Hassell KL, Umeh NI, de Montalembert M, Sahota P, et al. Clinical Outcomes Associated with Sickle Cell Trait: A Systematic Review. Ann Intern Med. 2018 Nov 6; 169(9):619-627. https://doi.org/10.7326/m18-1161
Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol. 2009;200(6): 620.e1‐620.e3. https://doi.org/10.1016/j.ajog.2009.01.038
Arlet JB, de Luna G, Khimoud D, Odièvre MH, de Montalembert M, Joseph L, et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. 2020 ; 7(9): e632-e634. https://dx.doi.org/10.1016%2FS2352-3026(20)30204-0
Britannica. The Editors of Encyclopaedia. hemoglobin. Encyclopedia Britannica. 2020. [Accessed 2022 Mar 08]. Available from: https://www.britannica.com/science/hemoglobin
CDC. Sickle Cell Disease and Prevention. 2021. [Accessed 2022 Mar 08]. Available from: https://www.cdc.gov/dotw/sickle-celldisease/index.html#:~:text=Prevention%20Tips&text=Prevent%20Infections%3A%20Common%20illnesses%20can,daily%20and%20eat%20healthy%20foods
Akhigbe RE, Ige SF, Afolabi AO, Azeez OM, Adegunlola GJ, Bamidele JO. Prevalence of Haemoglobin Variants, ABO and Rhesus blood groups in Ladoke Akintola University of Technology, Ogbomoso, Nigeria. Trends Med. Res. 2009; 4: 24-29. [Accessed 2022 Mar 08]. Available from: https://scialert.net/fulltext/?doi=tmr.2009.24.29
Medugu JT, Abjah U, Nasir IA, Adegoke S, Asuquo EE. Distribution of ABO, Rh D blood groups and hemoglobin phenotypes among pregnant women attending a Tertiary Hospital in Yola, Nigeria. J Med Tropics. 2016; 18(1): 38 42. https://doi.org/10.4103/2276-7096.177829
de Sanctis V, Canatan D, Corrons JLV, Karimi M, Daar S, Kattamis C, et al. Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study. Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1): e2020046. https://doi.org/10.4084/mjhid.2020.046
Ringelhann B, Hathorn MK, Jilly P, Grant F, Parniczky G. A new look at the protection of hemoglobin AS and AC genotypes against plasmodium falciparum infection: a census tract approach. Am J Hum Genet. 1976; 28(3): 270-9.
Okoroiwu HU, López-Muñoz F, Povedano-Montero FJ. Bibliometric analysis of global sickle cell disease research from 1997 to 2017. Hematol Transfus Cell Ther. 2020 Dec 28:S2531-1379(20)31305-5. https://doi.org/10.1016/j.htct.2020.09.156
Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathog. 2013; 9(5): e1003327. https://doi.org/10.1371/journal.ppat.1003327
Osibogun A, Balogun M, Abayomi A, Idris J, Kuyinu Y, Odukoya O, et al. Outcomes of COVID-19 patients with comorbidities in southwest Nigeria. PLoS One. 2021 Mar 15;16(3):e0248281. https://doi.org/10.1371/journal.pone.0248281
Akinboro A, Komolafe EK, Azeez MA. A retrospective study on Fourteen-year haemoglobin genotype variants recorded at five government hospitals in Akure Ondo State Southwestern Nigeria. Egypt J Med Human Genetics. 2016; 17(4): 377-381. https://doi.org/10.1016/j.ejmhg.2016.02.005
Kehinde, T.A., Osundiji, M.A., (2020). Sickle cell trait and the potential risk of severe coronavirus disease 2019—A mini‐review. Eur J Haematol. 2020 ;105(5):519-23. https://doi.org/10.1111/ejh.13478
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Otuonye NM et al